1093733-89-1Relevant academic research and scientific papers
Electrooxidative tandem cyclization ofN-propargylanilines with sulfinic acids for rapid access to 3-arylsulfonylquinoline derivatives
Li, Laiqiang,Liu, Jie,Wang, Lei,Wang, Min
, p. 4733 - 4740 (2021)
A series ofN-propargylanilines (0.2 mmol) and sulfinic acids (0.5 mmol) afforded 3-arylsulfonylquinoline derivatives in high yields (70-93%) and low current efficiencies upon electrooxidation. Electrolyses were carried out in a one-compartment cell, under
A visible-light-induced oxidative cyclization of: N -propargylanilines with sulfinic acids to 3-sulfonated quinoline derivatives without external photocatalysts
Zhang, Yicheng,Chen, Wei,Jia, Xueshun,Wang, Lei,Li, Pinhua
, p. 2785 - 2788 (2019/03/23)
A visible-light-induced oxidative cyclization of N-propargyl anilines with sulfinic acids was developed under external photocatalyst-free conditions. The reaction provides a straightforward route to 3-sulfonated quinoline derivatives with good functional
Discovery and Preclinical Characterization of 3-((4-(4-Chlorophenyl)-7-fluoroquinoline-3-yl)sulfonyl)benzonitrile, a Novel Non-acetylenic Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator for Psychiatric Indications
Galambos, János,Bielik, Attila,Krasavin, Mikhail,Orgován, Zoltán,Domány, Gy?rgy,Nógrádi, Katalin,Wágner, Gábor,Balogh, Gy?rgy T.,Béni, Zoltán,Kóti, János,Szakács, Zoltán,Bobok, Amrita,Kolok, Sándor,Mikó-Bakk, Mónika L.,Vastag, Mónika,Sághy, Katalin,Laszy, Judit,Halász, Attila Sándor,Balázs, Ottilia,Gál, Krisztina,Greiner, István,Szombathelyi, Zsolt,Keser?, Gy?rgy M.
, p. 2470 - 2484 (2017/04/03)
Negative allosteric modulators (NAM) of metabotropic glutamate receptor 5 (mGluR5) have been implicated as a potential pharmacotherapy for a number of psychiatric diseases, including anxiety and depression. Most of the mGluR5 NAM clinical candidates can be characterized by the central acetylenic moiety that connects the terminal pharmacophores. Identification of a sulfoquinoline hit via high throughput screening (HTS) followed by optimization provided a 4-phenyl-3-aryl-sulfoquinoline lead compound with the minimal pharmacophore. Optimization of the core and aryl appendages was performed by scanning and matrix libraries synthesized by the multiple parallel synthesis approach. Biological evaluation of matrix libraries provided a number of potent, metabolically stable, and in vivo active compounds. One of these compounds, 25 showed high efficacy and safety in preclinical in vivo models; this allowed its nomination as a novel, nonacetylenic mGluR5 NAM clinical candidate. Compound 25 was advanced to first-in-man trials for the treatment of psychiatric conditions.
SULFONYL-QUINOLINE DERIVATIVES
-
, (2009/01/23)
New mGluRl and mGluR5 receptor subtype preferring ligands of formula: (I) and/or salts and/or hydrates and/or solvates thereof, to the processes and intermediates for their preparation, to pharmaceutical compositions containing these compounds and to thei
